LDL apheresis can be used to lower blood LDL particles in selected patients with familial hypercholesterolemia (FH).
LDL apheresis is considered when both of the following are present:
(1) the patient fails to achieve an adequate response after >= 6 months of maximum tolerated drug therapy
(2) the patient shows certain patterns of laboratory and clinical findings
Parameters:
(1) type of FH
(2) serum cholesterol concentration
(3) risk factors (elevated blood pressure, smoking, obesity, physical inactivity, unhealthy diet)
Very high risk factors:
(1) established coronary artery disease
(2) other established vascular disease
(3) diabetes
Type of FH |
Cholesterol in mg/dL |
Risk Factors |
functional homozygous |
LDL-C >= 300 |
NA |
functional homozygous |
non-HDL-C >= 330 |
NA |
functional heterozygous |
LDL-C >= 300 |
0 or 1 |
functional heterozygous |
non-HDL-C >= 330 |
0 or 1 |
functional heterozygous |
LDL-C >=200 |
>= 2 or high lipoprotein(a) |
functional heterozygous |
non-HDL-C >= 230 |
>= 2 or high lipoprotein(a) |
functional heterozygous |
LDL-C >=160 |
very high risk |
functional heterozygous |
non-HDL-C >= 190 |
very high risk |
where:
• A high lipoprotein(a) concentration is >= 50 mg/dL using an isoform insensitive assay.
Specialty: Clinical Laboratory, Endocrinology